Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Momenta initiated with a Neutral at BTIG

BTIG analyst Thomas Shrader initiated Momenta (MNTA) with a Neutral rating, saying that while he is positive on the company's IVIg-focused re-positioning, the stock is not cheap and the proof-of-concept for its analytical focus is at least a year away.

The analyst also states that the bulk of his modeled value for the company comes from its pipeline development in treating maternal-fetal autoimmune disease, noting that competition in the space is "fierce" and that Momenta is "significantly behind Argenx (ARGX) in the development of FcRn blockers.

Read more at:
https://thefly.com/landingPageNews.php?id=2880297